Clinical UM Guideline
Subject: Hip Resurfacing
Guideline #: CG-SURG-85 Publish Date: 07/06/2022
Status: Reviewed Last Review Date: 05/12/2022

This document addresses partial and total hip resurfacing procedures, which are used as an alternative to total hip replacement surgery. In partial (hemi) hip resurfacing, a femoral shell is implanted over the femoral head to replace one side of the hip joint’s articular surface. In total hip resurfacing, a femoral shell is implanted over the femoral head and an acetabular shell is placed on the hip bone for the femur to fit into, thus “resurfacing” both sides of the hip joint.

Clinical Indications

Medically Necessary:

Partial Hip Resurfacing

Partial hip resurfacing of the femoral head is considered medically necessary in individuals with osteonecrosis of the femoral head with subchondral collapse.

Total Hip Resurfacing

Total hip resurfacing arthroplasty (HRA) is considered medically necessary in fit, active individuals who:

  1. Have normal proximal femoral bone geometry and bone quality; and
  2. Would otherwise receive a conventional primary total hip replacement (THR); and
  3. Are likely to live longer than a current conventional THR prosthesis is expected to last.

Not Medically Necessary:

Partial or total hip resurfacing is considered not medically necessary when criteria have not been met, and for all other indications not listed above.


The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services may be Medically Necessary when criteria are met:




Unlisted procedure, pelvis or hip joint [when specified as partial or total hip resurfacing]






Metal-on-metal total hip resurfacing, including acetabular and femoral components



ICD-10 Procedure



Supplement right hip joint with resurfacing device, open approach


Supplement left hip joint with resurfacing device, open approach


Supplement right hip joint, femoral surface with resurfacing device, open approach


Supplement left hip joint, femoral surface with resurfacing device, open approach



ICD-10 Diagnosis



All diagnoses

When services are Not Medically Necessary:
For the procedure codes listed above when criteria are not met and for all other indications.

Discussion/General Information

Hip replacement surgery aims to re-establish functional joint movement and alleviate pain associated with hip damage due to degenerative joint disease or trauma. Arthroplasty options for reconstruction of the hip include total hip replacement (THR), hemiarthroplasty (bipolar or unipolar), and partial or total hip resurfacing.

In the standard total hip replacement operation, the femoral head and neck are removed, and the femoral canal (marrow space) is reamed-out. The damaged hip joint is replaced with an artificial prosthesis composed of two or three different components:

In partial hip resurfacing, a femoral shell is implanted over the femoral head for avascular necrosis with collapse of the femoral head. This method acts to preserve the bone stock of the acetabulum.

In total hip resurfacing operations, the surgeon removes only the diseased or damaged surfaces of the head of the femur and the hip socket (acetabulum). The femoral head is fitted with a spherical shell and the hip socket is lined with a thin spherical cup. Both spherical cups form a pair of bearings which provide a low friction articulating surface. Total hip resurfacing has been investigated in a broader range of individuals including those with osteoarthritis, rheumatoid arthritis, and advanced avascular necrosis. It has been used as an alternative to total hip arthroplasty, particularly in young active individuals who would potentially outlive a total hip prosthesis. Therefore, total hip resurfacing could be viewed as a time-buying procedure to delay the need for a total hip arthroplasty.

Advantages of total hip resurfacing compared to total hip arthroplasty include preservation of the femoral neck and femoral canal, thus facilitating revision or conversion to a total hip replacement, if required. In addition, the resurfaced head is more similar in size to the normal femoral head, thus increasing the stability and decreasing the risk of dislocation compared to total hip arthroplasty.

At the present time, many devices have received either Pre-Market Approval (PMA) or 510K clearance from the FDA.

Other surgical interventions used to alleviate the symptoms of degenerative joint disease of the hip include, but are not limited to, osteotomy, arthrodesis and arthroscopy of the hip joint. Non-surgical interventions and medications can also be used to control these symptoms and delay or prevent the need for surgery. Once non-operative modalities have failed, femoral head-preserving procedures including grafting techniques, core decompression with vascularized or non-vascularized bone grafting, and upper femoral osteotomies have all been used with varying success.

Hemi (partial) hip resurfacing of the femoral head is an established procedure for individuals with osteonecrosis of the femoral head. In one case series of 33 hips, 91% of the devices were still implanted for a minimum of 5 years, with good or excellent results in 61%. Another case series of 37 prostheses followed for 7 years reported that 9 failed, requiring revision, but that 24 of the remaining 28 implants continued to function well with excellent or good hip scores. Several implant designs have been FDA approved for this purpose.

Total hip resurfacing has been proposed for instances when hemi hip resurfacing is insufficient, but total hip arthroplasty is considered inappropriate. At the present time, several total hip resurfacing devices have received  PMA from the FDA: the Birmingham Hip(Smith & Nephew Inc., Memphis, TN), the CONSERVE® Plus Total Resurfacing Hip System (Wright Medical Technologies, Arlington, TX), and the Cormet Hip Resurfacing System (Corin USA, Tampa, FL). Other devices, such as the Buechel-Pappas Integrated Total Hip Replacement (Endotec Inc., Santa Fe Springs, CA), which have previously received FDA PMA for total hip replacement, have also been granted 510k clearance for use in hip resurfacing procedures. The FDA’s 510k clearance differs from PMA in that 510k clearance does not require the submission and rigorous review of clinical trial data prior to the subject device being cleared for use in the market. Devices applying for 510k clearance need only prove that the subject device be substantially equivalent to a legally marketed device that is not subject to PMA. A substantially equivalent device is marketed subject to the same regulatory controls as the device to which it is found to be substantially equivalent. Manufacturers of devices that already have PMA, frequently seek 510k clearance for additional indications to expand the use of their devices. The Buechel-Pappas device is one example of this practice, having received PMA for use in total hip replacement surgery and subsequent 510k clearance for use in total hip resurfacing.

Interest in newer total hip resurfacing devices using different designs has increased in the light of high failure rates reported on the polyethylene-on-metal (PoM) prostheses (Head, 1982; Treuting, 1997). Standard hip resurfacing and replacement devices may use a metal femoral component and a polyethylene acetabular component. Research into the reason for failure of hip prostheses has discovered that a frequent reason for device failure is related to polyethylene debris created by friction and wear between the polyethylene articulating surface against the surface of the metal femoral component. This polyethylene debris collects in the joint space where it solicits an immune response. The immune response is not effective against the polyethylene particles, so the body’s defenses attack the bone adjacent to the prostheses, leading to bone loss and loosening of the implant (Beaule, 2002). The problem of debris collection and subsequent immune response is potentially greater in hip resurfacing procedures because resurfacing procedures involve the use of a femoral component with a much greater surface area compared to that used in total hip replacement procedures. It is proposed that this increase in surface area increases the volume of polyethylene debris in resurfacing procedures using PoM devices, thus increasing the likelihood of immune response and device failure. The results of a case series study including 114 individuals who underwent PoM hip resurfacing procedures reported a device survival rate of 47% over a 10-year period. The authors indicated that the survival of PoM hip resurfacing devices was deemed unacceptable (Duijsens, 2005). Newer device designs have been proposed to replace the PoM devices including ceramic-on-polyethylene (CoP) devices with ceramic femoral component and polyethelyene acetabular component, ceramic-on-ceramic (CoC) devices where both components are made from ceramic materials, and metal-on-metal (MoM) prostheses where both components are made from metal.

Of these newer device types, there is published evidence addressing the safety and efficacy focused on MoM devices. This includes several small to medium sized randomized controlled trials (RCTs), a few case-control studies, and a handful of case series studies. Vendittoli and colleagues (2006) report the results of an RCT comparing the 12-month outcomes of 102 individuals receiving MoM total hip replacement with 103 individuals receiving MoM total hip resurfacing procedures. In their article, they report no significant difference between the two groups on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) or Merle d’Aubigné-Postel scales. They also report a significantly higher activity level and quicker return to heavy or moderate activities in individuals undergoing the resurfacing when compared to those receiving replacement. Both techniques present similar complication rates of 15%. Another controlled trial by Pollard and colleagues (2006) describes 5- to 7-year outcomes of two groups of 54 individuals each of whom received MoM total hip resurfacing or total hip replacement. The authors report hip function was not significantly different between groups as measured by the Oxford hip score (OHS). However, scores from the University of California at Los Angeles activity scale and EuroQol life score both found significantly better outcomes in the hip resurfacing group. Revision rates were slightly lower in the resurfacing group (6% vs. 8%). De Smet (2005) describes the results of a large case series study of 252 individuals receiving MoM total hip resurfacing procedures followed for 3-5 years. The mean age of the study population was 49.7 years of age and the reported complication rate was 4.3% (n=11) and included sciatic nerve palsy (n=2) and heterotopic ossification Brooker grade 1 (n=3). The report indicates that results on the Harris Hip and Merle d’Aubigné-Postel scales indicate early clinical success in this population of predominantly young, active people. A study by the Canadian Arthroplasty Society (2013) of 2773 subjects who underwent total hip resurfacing and who were followed for a mean of 3.4 years indicates high prosthesis survival at 5 years (96.4%). The results of these studies are promising and indicate that MoM total hip resurfacing is an acceptable alternative to total hip replacement in younger people where bone conservation is a consideration in preparation for later total hip replacement surgery. However, it should be noted that not all devices provide the same outcomes. Langton and colleagues reported on the incidence of adverse reactions related to metal debris in a large case series study of 4226 MoM total hip resurfacing procedures (2010). Subjects received one of three different devices, two were the Birmingham and Conserve Plus devices available in the US, and the third was the Articular Surface Replacement (ASR; DePuy, Leeds, UK) which is not. The authors report significant differences between devices with regard to prosthesis failure, with subjects receiving the ASR at much higher risk compared to the two other devices. A retrospective cohort study involving 27,971 hip resurfacing procedures looked into the performance of different resurfacing devices (Jameson, 2012). The results of this study indicate that five brands of prosthesis had a significantly greater risk of revision than the Birmingham Hip (ASR: hazard ratio (HR), 2.82, p<0.001; Conserve: HR, 2.03, p<0.001; Cormet: HR, 1.43; p=0.001; Durom: HR, 1.67, p<0.001; Recap: HR, 1.58, p=0.007). Further research is needed to evaluate this issue.

Some studies have focused on optimization of patient selection for hip resurfacing. Langdon and others noted that individuals receiving smaller implants were at greater risk of failure (2010). This was also found in other studies. The Jameson study reported data indicating that women were at greater risk of revision than men (HR, 1.30, p=0.007), but the risk of revision was independent of age (2012). Additionally, they reported that smaller femoral head components were significantly more likely to require revision than medium or large heads (≤ 44 mm: HR, 2.14; p<0.001, 45 to 47 mm: HR, 1.48; p=0.001). Operations performed by low volume surgeons were also associated with higher risk of revision (HR, 1.36; p<0.001). Similar data were reported by Smith and colleagues, who presented data from the National Joint Registry for England and Wales, a database with information on 31,932 resurfacing cases (2012). They reported that at 5 years, women suffered greater risk of implant failure than men, irrespective of femoral head size (8.5% vs. 3.6%). Additionally, those with smaller femoral heads also fared worse than those with larger femoral heads. Multi-variate models for resurfacing procedures showed that head size was an independent predictor of revision for both men (p<0.0005) and women (p<0.0005).

In the Canadian Arthroplasty Society study (2013) mentioned above, males were more likely to have higher 5-year overall prosthesis survival compared to females (97.4% vs. 93.6%). Murray and colleagues published the results of a 10-year survival study of 554 subjects who were treated with the Birmingham hip (2012). In the female cohort (n=267), the 10-year survival was 74%, with a 10-year revision rate for pseudotumor of 7%, a mean OHS of 43 (standard deviation [SD] 8), and a mean UCLA activity score of 6.4 (SD 2). For the male cohort (n=379), 10-year survival was 95%, the 10-year revision rate for pseudotumor was 1.7%, the mean OHS was 45 (SD 6), and the mean UCLA score was 7.6 (SD 2). In the most demanding subgroup, comprised of male subjects aged < 50 years, treated for primary osteoarthritis, the survival was 99% (95% confidence interval [CI], 97 to 100).

Results of a systematic review reported by Haughom and others (2015) also reported that women demonstrated an increased likelihood of developing adverse local tissue reaction (odds ratio [OR], 5.70 [2.71-11.98]; p<0.001), dislocation (OR, 3.04 [1.2-7.5]; p=0.02), aseptic loosening (OR, 3.18 [2.21-4.58]; p<0.001), and revision (OR, 2.50 [2.25-2.78]; p<0.001) after primary MoM hip resurfacing arthroplasty. The authors stated that although femoral head size has been frequently implicated as a prime factor in the higher rate of complication in women, further research is necessary to specifically probe this relationship.

Additional studies with long follow-up times have reiterated the findings that females are at higher risk of MoM hip resurfacing arthroplasty when compared to males (Halawi, 2017; Matharu, 2016; Seppänen, 2017).

Major concern has been increasing with regard to the development of metallosis due to a high rate of chromium, cobalt, and titanium ion release from MoM prostheses. Several studies have demonstrated significantly high metal ion concentrations in whole blood and serum samples from individuals with MoM prostheses. Many of these studies have reported local soft tissue reactions to these high concentrations including aseptic lymphocytic vasculitis-associated lesion (ALVAL) and pseudotumor development (Isaac, 2009; Mahendra, 2009; Ollivere, 2009; Pandit, 2008; Smolders, 2011; Vendittoli, 2010). To date, the available studies addressing this issue have been small or have had significant methodological issues, and it is not yet possible to predict which individuals will experience adverse events related to metallosis. Additionally, the long-term result of elevated circulating blood metal ion concentrations is unknown. These observations are reiterated in the American Academy of Orthopedic Surgeons technology review on MoM hip implants (2011). Larger scale studies regarding MoM-related metallosis are needed to better understand this potential complication.

Several studies have been published addressing the long-term outcomes in subjects undergoing total hip resurfacing procedures. Matharu (2013) reported on the long-term outcomes of 393 subjects who were less than 50 years of age and underwent hip resurfacing with the Birmingham device in 474 hips. In this prospective case series study, all subjects were operated on by the same surgeon and followed for up to 14 years. No loss to follow-up was reported. A total of 16 (3.6%) implants underwent revisions at a mean of 6.2 years and no further surgical interventions were reported for any subject. The cumulative survival rates of all implanted Birmingham devices was 96.3% at 10 years and 84.1% at 14 years. The authors reported that females had a significantly increased risk of revision vs. males (p=0.047), and that decreasing femoral head size was associated with increased risk of revision (p=0.044). Measurements on the OHS improved from a preoperative mean of 19.2 to 46.0 at the last postoperative follow-up. Males had a significantly better median OHS score compared to females (3.1% vs. 6.3%; p=0.02). Similar findings were reported with regard to the UCLA score, with males scoring significantly higher than females (7.0 vs. 5.0; p=0.01). Radiographic studies at the last follow-up were available for 145 (45%) of the original cohort. No changes in acetabular component inclination angle or the femoral shaft angle were noted. Additionally, no evidence of osteolysis, loosening of components, or thinning of the femoral neck was reported. This study demonstrates good long-term outcomes for subjects implanted with the Birmingham hip device. However, this data must be viewed with the knowledge that all operations were conducted by a single surgeon in a specialty hospital with expertise in hip procedures. Results in other circumstances may vary considerably from those reported in this study.

In 2014, the same group published the results of a similar prospective case series study of 180 subjects, 65 years of age and older who underwent implantation of the Birmingham hip device (Pailhe, 2014). As with the study described above, all procedures were conducted by the same surgeon. Follow-up was 10 years, with no subjects lost. Revision arthroplasty was conducted in 3 subjects (1.7%). One was the result of high impact trauma, and not related to implant failure or any associated complications. Cumulative survival was 96.4% over the 10-year study period. As was reported by Matharu, devices in males had a significantly higher cumulative survival rate of 98.8% vs. 91.9% for females. The risk of revision increased with the subject age (HR, 1.42; p=0.014). Risk decreased with increasing femoral head size (HR, 0.682 for each millimeter (mm) increase; p=0.024). Revision risk was slightly decreased with male gender (HR, 0.048), but was not significant for females (HR, 4.079). Median absolute OHS was 50% preoperatively vs. 4.4% postoperatively. OHS was significantly better postoperatively in males vs. females (2.1% vs. 6.3%; p=0.021). Pelvic radiographs were available for 59% of all subjects not receiving revision surgery (105/177) at final follow-up. No changes in acetabular component inclination angle or the femoral shaft angle were noted, and no loosening of the components was reported. Asymptomatic heterotopic ossification was reported in 10 subjects (9.5%) and 3 cases of asymptomatic non-progressive femoral neck osteolysis were noted. Data on blood metal concentrations were collected from 15 subjects at a mean of 4.9 years. All samples were below recommended levels for chromium and cobalt. As with the previously described study, the long-term safety and efficacy of the Birmingham hip appears to be established in this cohort. However, the same cautions apply in the interpretation.

A study by Su et al. (2014) reported on the results of a prospective case series study of 265 subjects undergoing implantation of the Birmingham hip in 293 joints. There were eight separate surgeons participating in the study. At 2 years of follow-up, Harris Hip Scores improved significantly from a preoperative average of 56.8 to 96.9 postoperative (p<0.0001). At 4 years, the postoperative score was 70.0, with 97.65% reporting good or excellent results. Generic state of health measures were taken using the Euroqol-EQ-5D tool. Out of a maximum 100 points, subjects had an average score of 70.6 preoperatively, 88.5 at 1 year postoperatively, and 87.6 at 2 years (p<0.0001). Revision procedures were conducted for 7 subjects (2.4%) with the following complications: femoral neck fracture (n=2), pseudotumor reported (n=1), acetabular cup loosening (n=2), femoral implant loosening and femoral head osteonecrosis (n=1), and errant femoral implant placement (n=1). No statistical significance was noted for implant survivorship between genders (p=0.062), but significant variation between gender subgroups with regard to femoral head size (44.7 mm for females vs. 50.8 for males; p<0.0001). Heterotopic ossification was noted in 25.7% of radiographs at 2 years, but no osteolysis was reported. Blood metal ion testing was reported at 1 year post-operation for 276 hips, with median whole blood cobalt levels of 1.15 parts per billion (ppb) and median whole blood chromium levels of 1.7 ppb. At 4 years, blood metal ion data was available for 112 hips, with median whole blood cobalt levels of 1.56 parts per billion (ppb) and median whole blood chromium levels of 1.8 ppb. Both of these measures were significant on the Wilcox-Mann-Whitney test (p<0.0002 for cobalt and p<0.00001 for chromium). No significant differences were noted with regard to gender subgroups or to metal ion measurements. The authors reported that 8 subjects were above the 7 ppb threshold for metal ion concentrations, with 6 subjects having both elevated cobalt and chromium levels. In this high concentration subgroup, there was a significant gender difference, with 7.3% of females having metal ion levels greater than 7 ppb vs. 1% of males (p<0.0007). An analysis indicated that female gender resulted in an Odds Ratio (OR) of 10.7 for increased risk of elevated metal ion concentrations compared to males. However, none of the 8 subjects with elevated metal ion concentrations have undergone revision surgery and were asymptomatic at time of last follow-up. This data further supports the long-term safety and efficacy of the Birmingham hip device.

In 2018 and early 2019 multiple large long-term (5 to 10 years) studies were published (Amstutz, 2019; Dowding, 2019; Ford, 2018; Halawi, 2018; Scholes, 2019; Tao, 2018). These studies included several comparative trials. All reported outcomes similar to those of subjects who underwent THR, with excellent survivorship, complication and revision rates, and self-reported outcomes scores. None of the studies reported significant complications related to metalosis. Several described some significant differences related to gender, although one reported that these differences were remedied with a change in the implantation technique used (Amstutz, 2019). Multiple authors stated that their findings indicate that total hip resurfacing is an excellent option in younger and active individuals due well-preserved bone stock and restoration of the native anatomy.

Hellman and colleagues (2019) performed a systematic review of the literature using MEDLINE and EMBASE search engines. Inclusion criteria were level I to level III articles that reported clinical outcomes following primary surface replacement arthroplasty (SRA) compared with total hip arthroplasty (THA). An initial search yielded 2503 potential articles for inclusion. Exclusion criteria included review articles, level IV or level V evidence, less than 1 year's follow-up, and previously reported data. In total, 27 articles with 4182 individuals were available to analyze. The results showed that fracture and infection rates were similar between SRA and THA, while dislocation rates were lower in SRA compared with THA. SRA demonstrated equivalent patient-reported outcome scores with greater activity scores and a return to high-level activities compared with THA. SRA more reliably restored native hip joint biomechanics and decreased stress shielding of the proximal femur compared with THA. The study concluded that in young active men with osteoarthritis, there is evidence that SRA offers some potential advantages over THA, including: improved return to high-level activities and sport, restoration of native hip biomechanics, and decreased proximal femoral stress shielding. Continued long-term follow up is required to assess ultimate survivorship of SRA.

Vendittoli and colleagues (2020) performed a randomized follow-up study after a 2003 RCT was conducted. The 2003 RCT had 219 participants and the aim was to compare the clinical outcome between HR and 28-mm MoM THA. The aim of the follow-up study was to compare clinical scores and revision and complication rates after HR with those after THA. The inclusion criteria included those with degenerative hip disease and without femoral deformity that prevented HR, previous hip arthrodesis, renal insufficiency, known or suspected metal allergy, or known or suspected osteoporosis of the hip. The follow-up timeframe was from 14 to 16 years with a mean of 15 years and included participants with an age range between 18 and 65 years. All participants were managed by three hip surgeons in which the posterior surgical approach was used. In the follow-up study there were 203 participants in which 99 of those were in the THA group and received a CLS femoral stem (Zimmer) and an Allofit acetabular shell with a 28-mm Metasul chromium-cobalt bearing. The HR group had 104 participants and received a hybrid Durom resurfacing implant (Zimmer). The Kaplan-Meier survivorship, with revision for any reason as the end point, was 89.2% (95% CI, 82.3% to 96.1%) for HR and 94.2% (95% CI, 89.3% to 99.1%) for THA (p = 0.292). No dislocation occurred in the HR group compared with four dislocations in the THA group (p = 0.058). Both groups achieved a similar mean WOMAC score (10.7 in the HR group and 8.8 in the THA group; p = 0.749). There were three limitations identified for this follow-up study. The first limitation was that the study was not registered as it was conducted before registration was common or required. Secondly, the number of enrolled participants limited the power of the study. Thirdly, the researchers stated the results of their study were implant specific. The authors indicated that the results of the study might have been different with a THA using cross-linked polyethylene combined with a femoral head that was greater than 28 mm. After a review of their findings, the researchers concluded that HR remains an option for young and active individuals, when performed in the appropriate individual by surgeons who are properly trained and using validated prostheses.

Konan and colleagues (2021) studied the mid-term results of a prospective randomized controlled trial comparing large head MoM THA to MoM HR to determine if there was a difference between the two in regard to implant survival, participant reported outcomes and when performing functional tasks. The midterm follow-up was a minimum of 8 years (mean 9 years; range 8-10; SD 0.7). A total of 104 individuals were studied. Of this group, 56 (50 males) had MoM THA and 48 had HR (43 males). The mean age at surgery was 52 years in both groups. The results showed the revision rate in MoM THA group was 7 out of 56 (12.5%) and in the HR group it was 1 out of 48 (2.1%). A small group of individuals in both groups (6%) had poor participant reported outcome measures as indicated by low WOMAC pain scores (<70) suggesting possible impending failure. In the HR group, revision rate as well as functional outcome was noted as marginally better. The study was identified to have several limitations. The first limitation was that routine cross-sectional imaging and serum trace metal ion measurements were not undertaken in all participants. Secondly, the functional objective data that was measured using gait parameters was only available in a subset of the study participants. Finally, the study involved participants from a large geographical area which made it impossible to invite back every study participant for treadmill testing. The researchers concluded that the HR group had better functional parameters on gait-based tasks compared to the THA group but this difference did not reach statistical significance.

Hip resurfacing arthroplasty is considered an alternative to THA for those individuals that are deemed the best candidates for the procedure for example, younger, larger-framed and individuals with strong, healthy bone. Until the literature is more absolute, the decision to choose the best device design for the procedure such as MoM, CoC, CoP or PoM will be determined by the surgeon and the individual having the surgery to ensure the most optimal outcome of the procedure.


Peer Reviewed Publications:

  1. Adili A, Trousdale RT. Clinical orthopedics and related research number, femoral head re-surfacing for the treatment of osteonecrosis in the young patient. Clin Orthop Relat Res. 2003; (417):93-101.
  2. Amstutz, HC, Beaule PE, Dorey FJ, et al. Metal-on-metal hybrid surface arthroplasty: two to six-year follow-up study. J Bone Joint Surg Am. 2004; 86-A(1):28-39.
  3. Amstutz HC, Le Duff MJ. The mean ten-year results of metal-on-metal hybrid hip resurfacing arthroplasty. Bone Joint J. 2018; 100-B(11):1424-1433.
  4. Aulakh TS, Rao C, Kuiper JH, Richardson JB. Hip resurfacing and osteonecrosis: results from an independent hip resurfacing register. Arch Orthop Trauma Surg. 2010; 130(7):841-855.
  5. Beaulé PE, Amstutz HC, Le Duff M, Dorey F. Surface arthroplasty for osteonecrosis of the hip: hemiresurfacing versus metal-on-metal hybrid resurfacing. J Arthroplasty. 2004b; 19(8 suppl 3):54-58.
  6. Beaulé PE, Le Duff M, Campbell P, et al. Metal-on-metal surface arthroplasty with a cemented femoral component: a 7-10 year follow-up study. J Arthroplasty. 2004a; 19(8 Suppl 3):17-22.
  7. Canadian Arthroplasty Society. The Canadian Arthroplasty Society's experience with hip resurfacing arthroplasty. An analysis of 2773 hips. Bone Joint J. 2013; 95-B(8):1045-1051.
  8. Carrothers AD, Gilbert RE, Jaiswal A, Richardson JB. Birmingham hip resurfacing: the prevalence of failure. J Bone Joint Surg Br. 2010; 92(10):1344-1350.
  9. Clough EJ, Clough TM. Metal on metal resurfacing arthroplasty: where are we now? J Orthop. 2020; 23:123-127.
  10. Costa ML, Achten J, Parsons NR, et al.; Young Adult Hip Arthroplasty Team. Total hip arthroplasty versus resurfacing arthroplasty in the treatment of patients with arthritis of the hip joint: single centre, parallel group, assessor blinded, randomised controlled trial. BMJ. 2012; 344:e2147.
  11. Daniel J, Pynsent PB, McMinn DJ. Metal-on-metal resurfacing of the hip in patients under the age of 55 years with osteoarthritis. J Bone Joint Surg Br. 2004; 86(2):177-184.
  12. De Smet KA. Belgium experience with metal-on-metal surface arthroplasty. Orthop Clin North Am. 2005; 36(2):203-213, ix.
  13. Dowding C, Dobransky JS, Kim PR, Beaulé PE. Metal on metal hip resurfacing in patients 45 years of age and younger at minimum 5-year follow-up. J Arthroplasty. 2018; 33(10):3196-3200.
  14. Duijsens AW, Keizer S, Vliet-Vlieland T, Nelissen RG. Resurfacing hip prostheses revisited: failure analysis during a 16-year follow-up. Int Orthop. 2005; 29(4):224-228.
  15. Ford MC, Hellman MD, Kazarian GS, et al. Five to ten-year results of the Birmingham Hip Resurfacing Implant in the U.S.: a single institution's experience. J Bone Joint Surg Am. 2018; 100(21):1879-1887.
  16. Gerhardt DM, Smolders JM, Roovers EA, et al. Changes in periacetabular bone mineral density five years after resurfacing hip arthroplasty versus conventional total hip arthroplasty. Hip Int. 2019; 29(2):153-160.
  17. Gerhardt DMJM, Mors TGT, Hannink G, et al. Resurfacing hip arthroplasty better preserves a normal gait pattern at increasing walking speeds compared to total hip arthroplasty. Acta Orthop. 2019; 90(3):231-236.
  18. Girard J, Lavigne M, Vendittoli PA, Roy AG. Biomechanical reconstruction of the hip: a randomized study comparing total hip resurfacing and total hip arthroplasty. J Bone Joint Surg Br. 2006; 88-B(6):721-726.
  19. Grecula MJ. Resurfacing arthroplasty in osteonecrosis of the hip. Orthop Clin North Am. 2005; 36(2):231-242.
  20. Grigoris P, Roberts P, Panousis K, Jin Z. Hip resurfacing arthroplasty: the evolution of contemporary designs. Proc Inst Mech Eng H. 2006; 220(2):95-105.
  21. Halawi MJ, Brigati D, Messner W, Brooks PJ. Birmingham hip resurfacing in patients 55 years or younger: risk factors for poor midterm outcomes. J Arthroplasty. 2017; 32(6):1880-1883.
  22. Halawi MJ, Oak SR, Brigati D, et al. Birmingham hip resurfacing versus cementless total hip arthroplasty in patients 55 years or younger: a minimum five-year follow-up. J Clin Orthop Trauma. 201; 9(4):285-288.
  23. Harris WH. Wear and periprosthetic osteolysis: the problem. Clin Orthop Relat Res. 2001; (393):66-70.
  24. Haughom BD, Erickson BJ, Hellman MD, Jacobs JJ. Do complication rates differ by gender after metal-on-metal hip resurfacing arthroplasty? A systematic review. Clin Orthop Relat Res. 2015; 473(8):2521-2529.
  25. Head WC. The Wagner surface replacement arthroplasty. Orthop Clin North Am. 1982; 13(4):789-797.
  26. Hellman MD, Ford MC, Barrack RL. Is there evidence to support an indication for surface replacement arthroplasty?: a systematic review. Bone Joint J. 2019; 101B:32-40.
  27. Howie DW, McGee MA, Costi K, Graves SE. Metal-on-metal resurfacing versus total hip replacement-the value of a randomized clinical trial. Orthop Clin North Am. 2005; 36(2):195-201.
  28. Hungerford MW, Mont MA, Scott R, et al. Surface replacement hemiarthroplasty for the treatment of osteonecrosis of the femoral head. J Bone Joint Surg Am. 1998; 80(11):1656-1664.
  29. Huo M. What’s new in hip arthroplasty. J Bone Joint Surg Am. 2002; 84-A(10):1894-1905.
  30. Ingham E, Fisher J. The role of macrophages in osteolysis of total joint replacement. Biomaterials. 2005; 26(11):1271-1286.
  31. Jameson SS, Baker PN, Mason J, et al. Independent predictors of revision following metal-on-metal hip resurfacing: a retrospective cohort study using National Joint Registry data. J Bone Joint Surg Br. 2012; 94(6):746-754.
  32. Isaac GH, Siebel T, Oakeshott RD, et al. Changes in whole blood metal ion levels following resurfacing: serial measurements in a multi-centre study. Hip Int. 2009; 19(4):330-337.
  33. Kadoya Y, Kobayashi A, Ohashi H. Wear and osteolysis in total joint replacements. Acta Orthop Scand Suppl. 1998; 278:1-16.
  34. Kim PR, Beaulé PE, Laflamme GY, Dunbar M. Causes of early failure in a multicenter clinical trial of hip resurfacing. J Arthroplasty. 2008; 23(6 Suppl 1):44-49.
  35. Konan S, Waugh C, Ohly N, et al. Mid-term results of a prospective randomised controlled trial comparing large-head metal-on-metal hip replacement to hip resurfacing using patient-reported outcome measures and objective functional task-based outcomes. Hip Int. 2021; 31(5):637-643.
  36. Konttinen YT, Zhao D, Beklen A, et al. The microenvironment around total hip replacement prostheses. Clin Orthop Relat Res. 2005; (430):28-38.
  37. Langton DJ, Joyce TJ, Jameson SS, et al. Adverse reaction to metal debris following hip resurfacing: the influence of component type, orientation and volumetric wear. J Bone Joint Surg Br. 2011; 93(2):164-171.
  38. Lavigne M, Therrien M, Nantel J, et al. The John Charnley Award: The functional outcome of hip resurfacing and large-head THA is the same: a randomized, double-blind study. Clin Orthop Relat Res. 2010; 468(2):326-336.
  39. Lieberman JR, Berry DJ, Mont MA, et al. Osteonecrosis of the hip: management in the twenty-first century. J Bone Joint Surg Am. 2002; 84(5):834-853.
  40. Mahendra G, Pandit H, Kliskey K, et al. Necrotic and inflammatory changes in metal-on-metal resurfacing hip arthroplasties. Acta Orthop. 2009; 80(6):653-659.
  41. Matharu GS, Judge A, Murray DW, Pandit HG. Prevalence of and risk factors for hip resurfacing revision: a cohort study into the second decade after the operation. J Bone Joint Surg Am. 2016; 98(17):1444-1452.
  42. Matharu GS, McBryde CW, Pynsent WB, et al. The outcome of the Birmingham Hip Resurfacing in patients aged < 50 years up to 14 years post-operatively. Bone Joint J. 2013; 95-B(9):1172-1177.
  43. McGrath MS, Marker DR, Seyler TM, et al. Surface replacement is comparable to primary total hip arthroplasty. Clin Orthop Relat Res. 2009; 467(1):94-100.
  44. Mont MA, Marker DR, Smith JM, et al. Resurfacing is comparable to total hip arthroplasty at short-term follow-up. Clin Orthop Relat Res. 2009; 467(1):66-71.
  45. Mont MA, Rajadhyaksha AD, Hungerford DS. Outcomes of limited femoral resurfacing arthroplasty compared with total hip arthroplasty for osteonecrosis of the femoral head. J Arthroplasty. 2001; 16(8 Suppl 1):134-139.
  46. Mont MA, Seyler TM, Ragland PS, et al. Gait analysis of patients with resurfacing hip arthroplasty compared with hip osteoarthritis and standard total hip arthroplasty. J Arthroplasty. 2007; 22(1):100-108.
  47. Murray DW, Grammatopoulos G, Pandit H, et al. The ten-year survival of the Birmingham hip resurfacing: an independent series. J Bone Joint Surg Br. 2012; 94(9):1180-1186.
  48. Naudie DD, Engh CA Sr. Surgical management of polyethylene wear and pelvic osteolysis with modular uncemented acetabular components. J Arthroplasty. 2004; 19(4 Suppl 1):124-129.
  49. Nelson CL, Walz BH, Gruenwald JM. Resurfacing of only the femoral head for osteonecrosis. Long-term follow-up study. J Arthroplasty. 1997; 12(7):736-740.
  50. Ollivere B, Darrah C, Barker T, et al. Early clinical failure of the Birmingham metal-on-metal hip resurfacing is associated with metallosis and soft-tissue necrosis. J Bone Joint Surg Br. 2009; 91(8):1025-1030.
  51. Pailhe R, Matharu GS, Sharma A, et al. Survival and functional outcome of the Birmingham Hip Resurfacing system in patients aged 65 and older at up to ten years of follow-up. Int Orthop. 2014; 38(6):1139-1145.
  52. Pandit H, Glyn-Jones S, McLardy-Smith P, et al. Pseudotumours associated with metal-on-metal hip resurfacings. J Bone Joint Surg Br. 2008; 90(7):847-851.
  53. Pollard TC, Baker RP, Eastaugh-Waring SJ, Bannister GC. Treatment of the young active patient with osteoarthritis of the hip. A five- to seven-year comparison of hybrid total hip arthroplasty and metal-on-metal resurfacing. J Bone Joint Surg Br. 2006; 88(5):592-600.
  54. Schmalzried TP, Fowble VA, Ure KJ, Amstutz HC. Metal on metal surface replacement of the hip. Technique, fixation and early results. Clin Orthop Relat Res. 1996; (329 Suppl):S106-114.
  55. Scholes CJ, Ebrahimi M, Farah SB, et al. The outcome and survival of metal-on-metal hip resurfacing in patients aged less than 50 years. Bone Joint J. 2019; 101-B(1):113-120.
  56. Seppänen M, Karvonen M, Virolainen P, et al. Poor 10-year survivorship of hip resurfacing arthroplasty. Acta Orthop. 2016; 87(6):554-559.
  57. Siguier T, Siguier M, Judet T, et al. Partial resurfacing arthroplasty of the femoral head in avascular necrosis. Methods, indications, and results. Clin Orthop Relat Res. 2001; (386):85-92.
  58. Silva M, Lee KH, Heisel C, et al. The biomechanical results of total hip resurfacing arthroplasty. J Bone Joint Surg Am. 2004; 86-A(1):40-46.
  59. Smith AJ, Dieppe P, Howard PW, Blom AW; National Joint Registry for England and Wales. Failure rates of metal-on-metal hip resurfacings: analysis of data from the National Joint Registry for England and Wales. Lancet. 2012; 380(9855):1759-1766.
  60. Smith TO, Nichols R, Donell ST, Hing CB. The clinical and radiological outcomes of hip resurfacing versus total hip arthroplasty: a meta-analysis and systematic review. Acta Orthop. 2010; 81(6):684-695.
  61. Smolders JM, Hol A, Rijnberg WJ, van Susante JL. Metal ion levels and functional results after either resurfacing hip arthroplasty or conventional metal-on-metal hip arthroplasty. Acta Orthop. 2011; 82(5):559-566.
  62. Stulberg BN, Trier KK, Naughton M, Zadzilka JD. Results and lessons learned from a United States hip resurfacing investigational device exemption trial. J Bone Joint Surg Am. 2008; 90 Suppl 3:21-26.
  63. Su EP, Housman LR, Masonis JL, et al. Five year results of the first US FDA-approved hip resurfacing device. J Arthroplasty. 2014; 29(8):1571-1575.
  64. Tao R, Liu F, Liu YK, et al. A prospective comparative study of hip resurfacing arthroplasty and large-diameter head metal-on-metal total hip arthroplasty in younger patients-a minimum of five year follow-up. Int Orthop. 2018; 42(10):2323-2327.
  65. Treacy RB, McBryde CW, Pynsent PB. Birmingham hip resurfacing arthroplasty. A minimum follow-up of five years. J Bone Joint Surg Br. 2005; 87(2):167-170.
  66. Treuting RJ, Waldman D, Hooten J, et al. Prohibitive failure rate of the total articular replacement arthroplasty at five to ten years. Am J Orthop. 1997; 26(2):114-118.
  67. Vendittoli PA, Lavigne M, Girard J, Roy AG. A randomised study comparing resection of acetabular bone at resurfacing and total hip replacement. J Bone Joint Surg Br. 2006; 88(8):997-1002.
  68. Vendittoli PA, Lavigne M, Roy AG, Lusignan D. A prospective randomized clinical trial comparing metal-on-metal total hip arthroplasty and metal-on-metal total hip resurfacing in patients less than 65 years old. Hip Int. 2006; 16 Suppl 4:73-81.
  69. Vendittoli PA, Roy A, Mottard S, et al. Metal ion release from bearing wear and corrosion with 28 mm and large-diameter metal-on-metal bearing articulations: a follow-up study. J Bone Joint Surg Br. 2010; 92(1):12-19.
  70. Vendittoli PA, Shahin M, Riviere C, et al. Hip resurfacing compared with 28-mm metal-on-metal total hip replacement: a randomized study with 15 year follow-up. J Bone Joint Surg Am. 2020; 102(Suppl 2) 80-90.

Government Agency, Medical Society, and Other Authoritative Publications:

  1. Agency for Healthcare Research and quality. Horizon Scan on Hip Replacement Surgery. December 22, 2006.
  2. Blue Cross Blue Shield Association. Metal-on-metal total hip resurfacing. TEC Assessment. 2007. 22(3).
  3. Bozic KJ, Browne J, Danhgles CJ, et al. Modern metal-on-metal hip implants: a technology overview. J Am Acad Orthop Surg June 2012; 20(6):402-406.
  4. Lombardi AV Jr, Barrack RL, Berend KR, et al. The Hip Society: algorithmic approach to diagnosis and management of metal-on-metal arthroplasty J Bone Joint Surg Br. 2012; 94(11 Suppl A):14-18.
  5. National Institute for Health and Care Excellence (NICE). Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip. February 26, 2014. Available at: Accessed on April 29, 2022.
  6. U.S. Food and Drug Administration. Concerns about Metal-on-Metal Hip Implant Systems. Updated on March 15, 2019. Available at:
    . Accessed on April 29, 2022.
  7. U.S. Food and Drug Administration. Information for orthopaedic surgeons: general recommendations for orthopaedic surgeons before metal-on-metal hip resurfacing surgery. Updated on March 15, 2019. Available at: Accessed on April 29, 2022.
  8. U.S. Food and Drug Administration. Metal-on-Metal Hip Implants: FDA Activities. Updated on March 15, 2019. Available at:
    . Accessed on April 29, 2022.

Birmingham Hip Resurfacing (BHR) System
Buechel-Pappas Integrated Total Hip Replacement
Conserve Plus
Cormet 2000
Cormet Hip Resurfacing System

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.







Medical Policy & Technology Assessment Committee (MPTAC) review. Updated Discussion/General Information and References sections.



MPTAC review. Combined two NMN statements into one NMN statement in the Clinical Indications section. Updated Discussion/General Information and References sections. Reformatted Coding section.



MPTAC review. Updated formatting of MN clinical indications section. Updated background and references sections.



MPTAC review. Removed text from medically necessary statements related to FDA approval status. Updated Rationale and References sections.



MPTAC review. Initial document development. Moved content of SURG.00051 Hip Resurfacing to new clinical utilization management guideline document with the same title.











Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only - American Medical Association